Sonendo announces David Caluori to its Board along with raising $50m strategic investment led by General Atlantic

– USA, CA – Sonendo, Inc., a leading dental technology company, announced today that General Atlantic, a leading global growth equity firm, has made a strategic investment in the company. General Atlantic will be joining existing investors Fjord Ventures, OrbiMed Advisors LLC, Meritech Capital Partners, CVF LLC, and NeoMed to lead the company’s latest fundraising round valued at $50 million. In its next phase of growth, Sonendo plans to accelerate ongoing commercialization efforts and further expand and diversify its current product portfolio.

“Sonendo is committed to developing technologies that are transformative and align with our mission of Saving Teeth Through Sound Science®,” said Bjarne Bergheim, President, and CEO of Sonendo. “With its strong track record partnering with successful, high-growth companies in the healthcare sectors, General Atlantic is an ideal partner for our next phase of growth.”

Founded in 2006 by Fjord Ventures, Sonendo, Inc. is devoted to developing innovative technologies to help dentists save more teeth for more patients. Sonendo’s flagship technology, the GentleWave® System, presents an alternative to standard root canal treatment and a departure from the standard file-based method of tissue removal and disinfection for root canals.

“We believe there is a unique opportunity for Sonendo to transform the dental industry with its innovative technology that benefits both dentists and patients alike,” said David Caluori of General Atlantic, who will be joining the company’s board of directors. “We look forward to partnering with Bjarne and the entire management team to support the company’s growth and commitment to developing unique technology intended for a market of underserved consumers and dentists.”

Drawing from 37 years of experience investing in over 250 global growth companies, General Atlantic partners with entrepreneurs and management teams who are building leading, high-growth businesses. The firm has $21 billion assets under management as of June 30, 2017. General Atlantic focuses on investments across five sectors, including Internet & Technology, Financial Services, Business Services, Retail & Consumer, and Healthcare, with support from the firm’s global team of experts.

General Atlantic has deep expertise in the Healthcare and Technology sectors and is currently invested in leading healthcare companies including Alignment Healthcare, CitiusTech, eviCore Healthcare, Oak Street Health, Ourofino, Sanfer, and Synaptive.

About Sonendo

Sonendo, Inc. is a privately-held company developing innovative and disruptive technologies to transform dentistry by Saving Teeth Through Sound Science. The first commercially available product from Sonendo, the GentleWave System, available in the US, shows significant improvements in clinical efficacy, and treatment efficiency when compared to standard root canal techniques1-2.

For more information : http://www.sonendo.com

About General Atlantic

General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build exceptional businesses worldwide. General Atlantic has more than 100 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, London, Mexico City, Mumbai, Munich, Palo Alto, Sao Paulo, and Singapore.

For more information : http://www.generalatlantic.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.